ST2 is a unique biomarker reflecting cardiac fibrosis and remodeling and is extensively validated for use in the prognosis and risk assessment of patients with chronic heart failure.

ST2 enables you to assess risk, and clearly discern between low and high risk heart failure patients and provide focused care to those who need it most. And because ST2 levels change rapidly, you now have an aid, in addition to other clinical parameters, to adjust care, if needed.
ST2 is driving the paradigm shift in how you manage your chronic heart failure patients!

Yorum yok

İlk yorumu yazan siz olun

Yorum yaz

İsminizi yazınız Lütfen geçerli bir email adresi yazınız Lütfen mesajınızı yazınız